CO2022001482A2 - Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida - Google Patents
Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidaInfo
- Publication number
- CO2022001482A2 CO2022001482A2 CONC2022/0001482A CO2022001482A CO2022001482A2 CO 2022001482 A2 CO2022001482 A2 CO 2022001482A2 CO 2022001482 A CO2022001482 A CO 2022001482A CO 2022001482 A2 CO2022001482 A2 CO 2022001482A2
- Authority
- CO
- Colombia
- Prior art keywords
- methyl
- methoxyazetidin
- dihydropyridin
- dioxole
- methylthio
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción se refiere a una Forma cristalina 1 de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida, que es útil como modulador de la actividad de las enzimas modificadoras de metilo de las histonas. La presente descripción también proporciona composiciones farmacéuticamente aceptables que comprenden la forma cristalina y métodos para usar dichas composiciones en el tratamiento de diversos trastornos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962878012P | 2019-07-24 | 2019-07-24 | |
PCT/US2020/043178 WO2021016414A1 (en) | 2019-07-24 | 2020-07-23 | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022001482A2 true CO2022001482A2 (es) | 2022-03-18 |
Family
ID=72047059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0001482A CO2022001482A2 (es) | 2019-07-24 | 2022-02-15 | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220251073A1 (es) |
EP (1) | EP4003532A1 (es) |
JP (1) | JP2022541630A (es) |
KR (1) | KR20220041129A (es) |
AU (1) | AU2020316073A1 (es) |
BR (1) | BR112022001161A2 (es) |
CA (1) | CA3148447A1 (es) |
CL (1) | CL2022000175A1 (es) |
CO (1) | CO2022001482A2 (es) |
IL (1) | IL289972A (es) |
MX (1) | MX2022000931A (es) |
PE (1) | PE20220562A1 (es) |
WO (1) | WO2021016414A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11919912B2 (en) | 2018-05-21 | 2024-03-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
KR20230110210A (ko) * | 2022-01-14 | 2023-07-21 | 동화약품주식회사 | 1,3-벤조다이옥솔 유도체 화합물 및 이를 포함하는 약학적 조성물 |
WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
WO2024015566A1 (en) | 2022-07-15 | 2024-01-18 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibition therapies for the treatment of at-rich interactive domain-containing protein 1a (arid1a) mutated cancers |
CN115403040B (zh) * | 2022-08-11 | 2023-08-01 | 中国地质大学(北京) | 一种可通过光辐射调控导热系数的偶氮苯聚合物表面修饰的金刚石纳米粒子及其制备方法 |
WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
WO2024076663A1 (en) | 2022-10-06 | 2024-04-11 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibition therapies for the treatment of brca1-associated protein (bap1) mutated cancers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE049417T2 (hu) * | 2014-03-17 | 2020-09-28 | Daiichi Sankyo Co Ltd | 1,3-benzodioxol származékok mint EZHl és/vagy EZH2 inhibitorok |
MA52288A (fr) * | 2018-04-18 | 2021-04-07 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci |
-
2020
- 2020-07-23 MX MX2022000931A patent/MX2022000931A/es unknown
- 2020-07-23 JP JP2022504532A patent/JP2022541630A/ja active Pending
- 2020-07-23 PE PE2022000116A patent/PE20220562A1/es unknown
- 2020-07-23 EP EP20754482.6A patent/EP4003532A1/en active Pending
- 2020-07-23 CA CA3148447A patent/CA3148447A1/en active Pending
- 2020-07-23 AU AU2020316073A patent/AU2020316073A1/en active Pending
- 2020-07-23 US US17/628,947 patent/US20220251073A1/en active Pending
- 2020-07-23 KR KR1020227005690A patent/KR20220041129A/ko unknown
- 2020-07-23 BR BR112022001161A patent/BR112022001161A2/pt unknown
- 2020-07-23 WO PCT/US2020/043178 patent/WO2021016414A1/en unknown
-
2022
- 2022-01-19 IL IL289972A patent/IL289972A/en unknown
- 2022-01-24 CL CL2022000175A patent/CL2022000175A1/es unknown
- 2022-02-15 CO CONC2022/0001482A patent/CO2022001482A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20220562A1 (es) | 2022-04-13 |
KR20220041129A (ko) | 2022-03-31 |
CA3148447A1 (en) | 2021-01-28 |
JP2022541630A (ja) | 2022-09-26 |
CN114450279A (zh) | 2022-05-06 |
WO2021016414A1 (en) | 2021-01-28 |
BR112022001161A2 (pt) | 2022-06-07 |
EP4003532A1 (en) | 2022-06-01 |
IL289972A (en) | 2022-03-01 |
US20220251073A1 (en) | 2022-08-11 |
AU2020316073A1 (en) | 2022-02-17 |
CL2022000175A1 (es) | 2022-09-20 |
MX2022000931A (es) | 2022-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022001482A2 (es) | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida | |
CL2019002664A1 (es) | Administración rápida y controlada de composiciones con efectos séquito restaurados. | |
CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
AR098693A1 (es) | Método para producir células del epitelio pigmentario retiniano (rpe) | |
CO7240408A2 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
CO2021007993A2 (es) | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina | |
AR090970A1 (es) | Diferenciacion de celulas madre humanas embrionarias en endodermo pancreatico | |
CR9723A (es) | Nueva forma cristalina de un derivado de piridazino[4,5-b] indol | |
AR086281A1 (es) | Composiciones y metodos que comprenden variantes de serina proteasas | |
ECSP20068210A (es) | Moduladores calpaína y usos terapéuticos de los mismos | |
UY33832A (es) | Inhibidores de la faah. | |
CL2021002963A1 (es) | Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer | |
PE20160519A1 (es) | Compuestos de tetrahidrocarbozol y carbozol carboxamida sustituidos utiles como inhibidores de cinasa | |
NI201600149A (es) | Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasa | |
BR112017007545A2 (pt) | derivados de carbazol | |
CL2016002827A1 (es) | Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos. | |
PE20151142A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
BR112016000658A2 (pt) | pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática | |
CO2019007879A2 (es) | Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización | |
CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
CO2020004407A2 (es) | Formulaciones de espora de nutriente y usos de las mismas | |
AR126447A1 (es) | INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS | |
CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
CO2022017233A2 (es) | 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis | |
CO2020007772A2 (es) | Método para el cultivo de células |